MedTrace Logo

Rate Control in Atrial Fibrillation II

NCT02695992 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2022-01-05

No results posted yet for this study

Summary

The RATAF II study is a randomized, prospective, parallel group study, designed to compare the effects of two different drug regimens for rate control in permanent AF (atrial fibrillation). We will investigate on the difference in effects on exercise capacity, biomarkers (NT-proBNP (N-terminal pro-brain natriuretic peptide), troponins, hs-CRP), heart rate, echocardiographic measurements and symptoms.

Our main hypothesis is that six months' treatment with the calcium channel blocker diltiazem will lower NT-proBNP and increase exercise capacity (peak VO2) compared to treatment with the beta blocker metoprolol in permanent AF.

Conditions

Interventions

DRUG

Metoprolol

Dosage 100 mg o.d.

DRUG

Diltiazem

Dosage 360 mg o.d.

Sponsors & Collaborators

  • Vestre Viken Hospital Trust

    collaborator OTHER

  • Helse Sor-Ost

    collaborator OTHER_GOV

  • Asker & Baerum Hospital

    lead OTHER

Principal Investigators

  • Sara Reinvik Ulimoen, MD PhD · Vestre Viken HF Baerum Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2021-10-31
Completion
2021-11-12

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02695992 on ClinicalTrials.gov